3. The bias towards known targets seems counterintuitive. Given that mTOR has 38,020 PubMed hits and ChEMBL has 4,557 compounds aligned against P42345 (including 20 clinical candidates), the need for 5 experimental and 225 calculated probes is not obvious (although new highly selective and potent allosteric modulators of old targets could provide new insights). As the Pharos TLD categories indicate, probes development that would broaden Tchem and make inroads into Tdark could lead to functional illumination (but with the caveat of the obvious paucity of assays for understudied proteins).